Our Lady's Hospice & Care Services, Dublin, Ireland.
Arthritis Care Res (Hoboken). 2014 Nov;66(11):1597-603. doi: 10.1002/acr.22387.
To determine the relationship between fatigue and the American College of Rheumatology (ACR) core set outcomes in patients with inflammatory arthritis (IA).
This prospective longitudinal study evaluated fatigue in patients with active IA commencing tumor necrosis factor (TNF) inhibitor therapy. Fatigue was assessed using the multidimensional assessment of fatigue scale and the ACR core set (swollen and tender joint counts, pain, global health score, Health Assessment Questionnaire [HAQ] disability index [DI], and C-reactive protein level) was used for standard assessment of disease activity.
Assessments at baseline, 3 months, and 6 months were completed by 125, 92, and 82 patients, respectively. Fatigue and disease activity improved significantly within the first 3 months, with fatigue improving by 29% (F[2, 118] = 17.14, P < 0.001; repeated-measures analysis of variance). Using multiple regression, the amount of fatigue explained by the core outcomes differed at each time point: 28% at baseline (P < 0.001; significant predictors were the HAQ DI, global health, and C-reactive protein level), 37% at 3 months (P < 0.001; significant predictors were pain and tender joint count), and 46% at 6 months (P < 0.001; significant predictor was global health). Regression modelling using the fatigue change score at 3 months explained 17% of fatigue change (P < 0.012; significant predictors were HAQ DI and global health).
Fatigue, which improved following treatment with TNF inhibitors, was poorly and inconsistently explained through the core set outcomes. Further, fatigue was least accounted for when the disease was most active, highlighting the need for further research into alternate explanations. These findings suggest further exploration of contributing variables and mechanisms in order to develop targeted symptom management of fatigue in IA.
确定疲劳与炎症性关节炎(IA)患者的美国风湿病学会(ACR)核心标准结局之间的关系。
本前瞻性纵向研究评估了开始使用肿瘤坏死因子(TNF)抑制剂治疗的活动性 IA 患者的疲劳情况。使用多维疲劳评估量表和 ACR 核心标准(肿胀和压痛关节计数、疼痛、总体健康评分、健康评估问卷 [HAQ] 残疾指数 [DI] 和 C 反应蛋白水平)评估疲劳,用于疾病活动的标准评估。
分别有 125、92 和 82 名患者完成了基线、3 个月和 6 个月的评估。在最初的 3 个月内,疲劳和疾病活动明显改善,疲劳改善了 29%(F[2, 118] = 17.14,P < 0.001;重复测量方差分析)。使用多元回归,核心结局解释的疲劳量在每个时间点都有所不同:基线时为 28%(P < 0.001;显著预测因子为 HAQ DI、总体健康和 C 反应蛋白水平),3 个月时为 37%(P < 0.001;显著预测因子为疼痛和压痛关节计数),6 个月时为 46%(P < 0.001;显著预测因子为总体健康)。使用 3 个月时的疲劳变化评分进行回归建模,可解释 17%的疲劳变化(P < 0.012;显著预测因子为 HAQ DI 和总体健康)。
TNF 抑制剂治疗后疲劳得到改善,但通过核心标准结局解释得很差且不一致。此外,当疾病最活跃时,疲劳的解释程度最低,这突出了需要进一步研究替代解释。这些发现表明,需要进一步探索相关变量和机制,以便对 IA 中的疲劳进行有针对性的症状管理。